CLINICAL_TRIALS
trial_result
· 2023-07-03
Clinical Trial Update: Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) [Phase 3]
Summary
A phase 3 study evaluating the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Concert Pharmaceuticals | Conditions: Alopecia Areata | Phase 3 | Status: COMPLETED | Results posted: 2023-07-03